Preclinical antitumor activity of the TLR7/8 agonist vesatilomod combined with the HDAC inhibitor romidepsin as a new therapeutic concept for the treatment of colorectal carcinoma

被引：0
|
作者：
Strumberg, D. [1 ]
Asif, R. H. [1 ]
Acikelli, A. H. [1 ]
Noa-Bolano, A. [1 ]
D'Souza, F. [1 ]
Klein, J. [1 ]
Diaz-Carballo, D. [1 ]
机构：
[1] Inst Mol Oncol & Expt Therapeut, Dept Hematol & Oncol, Herne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1000
引用
收藏
页码：313 / 313
页数：1
相关论文
共 13 条
  • [1] Antitumor Activity of An RNA-Based Agonist of TLR7 and 8 In Preclinical Models of Hematological Malignancies
    Wang, Daqing
    Precopio, Melissa
    Reardon, Michael
    Lan, Tao
    Tang, Jimmy X.
    Kandimalla, Ekambar R.
    La Monica, Nicola
    Agrawal, Sudhir
    BLOOD, 2010, 116 (21) : 188 - 188
  • [2] Combined treatment with PD-L1 blockade and a TLR7/8 agonist dramatically enhances antitumor immunity
    Nishii, Naoto
    Kondo, Yuta
    Li, Lixin
    Lau, Walter
    Harada, Hiroyuki
    Azuma, Miyuki
    CANCER RESEARCH, 2016, 76
  • [3] Antitumor activity of a dual agonist of TLR7 and TLR8 in combination with bevacizumab in preclinical models of human non-small cell lung and colon cancers
    Wang, Daqing
    Lan, Tao
    Tang, Jimmy
    Kandimalla, Ekambar
    Agrawal, Sudhir
    CANCER RESEARCH, 2009, 69
  • [4] Antitumor activity of a novel dual agonist of TLR7 and TLR8 in a preclinical model of 3LL-C75 lung carcinoma in wild type, TLR7-/-, TLR9-/-, and MyD88-/- mice
    Wang, Daqing
    Tao, Lan
    Tang, Jimmy
    Kandimalla, Ekambar
    Agrawal, Sudhir
    CANCER RESEARCH, 2009, 69
  • [5] Antitumor activity of a novel dual agonist of TLR7 and TLR8 in a preclinical model of 3LL-C75 lung carcinoma in wild type, TLR7-/-, TLR94-/-, and MyD884-/- mice
    Wang, Daqing
    Tao, Lan
    Tang, Jimmy
    Kandimalla, Ekambar
    Agrawal, Sudhir
    CANCER RESEARCH, 2009, 69
  • [6] IMO-4200, a Novel TLR7 and TLR8 Dual Agonist, Enhances Antitumor Effect of Ofatumumab, Rituximab and Cytotoxics in Preclinical Models of Hematological Malignancies
    Wang, Daqing
    Precopio, Melissa
    Reardon, Michael J.
    Lan, Tao
    Tang, Jimmy X.
    Kandimalla, Ekambar R.
    Bexon, Alice
    La Monica, Nicola
    Agrawal, Sudhir
    BLOOD, 2011, 118 (21) : 1591 - 1591
  • [7] Combinations with TLR7/8 agonists and reactivated HERV elements by "latency reversing agents" as a new therapeutic concept for the treatment of lymphoid and myeloid blasts
    Acikelli, A. H.
    Carballo, Diaz D.
    Rahner, U.
    Noa-Bolano, A.
    D'Souza, F.
    Klein, J.
    Strumberg, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 279 - 280
  • [8] Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model
    Liou, An-Ting
    Liao, Chun-Che
    Chou, Shu-Fan
    Chang, Ya-Shu
    Chang, Chih-Shin
    Shih, Chiaho
    JOURNAL OF BIOMEDICAL SCIENCE, 2019, 26 (01)
  • [9] Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model
    An-Ting Liou
    Chun-Che Liao
    Shu-Fan Chou
    Ya-Shu Chang
    Chih-Shin Chang
    Chiaho Shih
    Journal of Biomedical Science, 26
  • [10] Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
    Mullins, Stefanie R.
    Vasilakos, John P.
    Deschler, Katharina
    Grigsby, Iwen
    Gillis, Pete
    John, Julius
    Elder, Matthew J.
    Swales, John
    Timosenko, Elina
    Cooper, Zachary
    Dovedi, Simon J.
    Leishman, Andrew J.
    Luheshi, Nadia
    Elvecrog, James
    Tilahun, Ashenafi
    Goodwin, Richard
    Herbst, Ronald
    Tomai, Mark A.
    Wilkinson, Robert W.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
12